455 results on '"Feliu, J."'
Search Results
2. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
- Author
-
Ghanem, I., Lora, D., Herradón, N., de Velasco, G., Carretero-González, A., Jiménez-Varas, M.Á., Vázquez de Parga, P., and Feliu, J.
- Published
- 2022
- Full Text
- View/download PDF
3. Self-Reported Menstrual Alterations During the COVID-19 Syndemic in Spain: A Cross-Sectional Study
- Author
-
Medina-Perucha L, López-Jiménez T, Holst AS, Jacques-Aviñó C, Munrós-Feliu J, Martínez-Bueno C, Valls-Llobet C, Pinzón-Sanabria D, Vicente-Hernández MM, and Berenguera A
- Subjects
menstruation ,covid19 ,long covid19 ,menstrual health ,menstrual inequity ,women’s health ,Gynecology and obstetrics ,RG1-991 - Abstract
Laura Medina-Perucha,1,2 Tomàs López-Jiménez,1,2 Anna Sofie Holst,1,3 Constanza Jacques-Aviñó,1,2 Jordina Munrós-Feliu,4,5 Cristina Martínez-Bueno,5,6 Carme Valls-Llobet,7 Diana Pinzón-Sanabria,8 Mª Mercedes Vicente-Hernández,5 Anna Berenguera1,2,9 1Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; 2Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Barcelona, Spain; 3Universitat Pompeu Fabra, Barcelona, Spain; 4Atenció a la Salut Sexual i Reproductiva (ASSIR) Muntanya/La Mina, Institut Català de la Salut, Barcelona, Spain; 5Sexual and Reproductive Health Care Research Group (GRASSIR), Barcelona, Spain; 6Servei d’Atenció a la Salut Sexual i Reproductiva (ASSIR), Direcció Assistencial d’Atenció Primària, Institut Català de la Salut, Barcelona, Spain; 7Centro de Análisis y Programas Sanitarios (CAPS), Barcelona, Spain; 8SomiArte Taller, Barcelona, Spain; 9Departament d’Infermeria, Universitat de Girona, Girona, SpainCorrespondence: Laura Medina-Perucha, Gran Via de les Corts Catalanes 587 attic, Barcelona, 08007, Spain, Tel +34 934824253, Email lmedina@idiapjgol.orgIntroduction: Available evidence suggests that there might be an association between the stressors experienced during the COVID-19 syndemic and changes in menstrual patterns. The aim of this study was to assess self-reported menstrual alterations during the COVID-19 syndemic among women and people who menstruate aged 18– 55 in Spain.Materials and Methods: A cross-sectional online survey-based study was conducted (March–July 2021). Descriptive statistics were calculated and multivariate logistic regression models were constructed. This study was conducted as part of the “Equity and Menstrual Health in Spain” research project.Results: Among participants (N=17,455), 39.4% reported menstrual alterations since the start of the syndemic. Participants self-reporting long COVID-19 presented higher odds of menstrual alterations (aOR: 1.34, 95% CI, 1.15-1.57). In participants with no history of COVID-19, the risk for self-reported menstrual alterations was significantly higher based on employment situation, among participants experiencing financial issues (eg, financial issues always/many times < 12 months: aOR: 1.68, 95% CI, 1.48– 1.90), poorer self-perceived health (eg, poor: aOR: 2.00, 95% CI, 1.31– 3.07), and those diagnosed with polycystic ovary syndrome (aOR: 1.13, 95% CI, 1.02– 1.26). Among participants with a self-reported COVID-19 diagnosis, factors that significantly increased the odds for menstrual alterations were experiencing financial strains (eg, financial issues always/many times < 12 months: aOR: 1.53, 95% CI, 1.09– 2.14), poorer self-perceived health (eg, poor: aOR: 3.09, 95% CI, 1.01– 9.52). Overall, factors that decreased the odds of reporting menstrual alterations included age > 25, being a carer, not having a gynecological condition and using hormonal contraception.Discussion and conclusions: Findings suggest an impact of the COVID-19 syndemic on menstrual patterns. Social inequities in reporting menstrual alterations were identified. While the risk of reporting menstrual alterations was higher among participants with long COVID-19, evidence is not conclusive. Further research on menstrual health in the context of COVID-19 is needed, also to inform policy and practice.Keywords: menstruation, COVID-19, long COVID-19, menstrual health, menstrual inequity, women’s health
- Published
- 2022
4. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review
- Author
-
Solares, I., Viñal, D., Morales-Conejo, M., Rodriguez-Salas, N., and Feliu, J.
- Published
- 2021
- Full Text
- View/download PDF
5. 243P Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in metastatic breast cancer patients
- Author
-
Criado, J. Álvarez, primary, Martinez, V.M., additional, Aunon, M.P. Zamora, additional, Peña-López, J., additional, Sanchez, V.L. Collada, additional, Espinosa, E., additional, Hoyo-Muñoz, A., additional, García-López, L., additional, Mateos-Salillas, C., additional, Perez, D. Martinez, additional, Castelo, B., additional, Ruiz-Gutiérrez, I., additional, Cuesta, J.A. Garcia, additional, Bou, D. Jiménez, additional, Recio, S. Martinez, additional, Barbas, J. Pedregosa, additional, Feliu, J., additional, and Herrero, A., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Menstrual inequity in Spain: a cross-sectional study
- Author
-
Medina-Perucha, L, primary, López-Jiménez, T, additional, Jacques-Aviñó, C, additional, Holst, AS, additional, Valls-Llobet, C, additional, Munrós-Feliu, J, additional, Martínez-Bueno, C, additional, Pinzón-Sanabria, D, additional, Vicente-Hernández, MM, additional, and Berenguera, A, additional
- Published
- 2022
- Full Text
- View/download PDF
7. 383P An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials
- Author
-
Goel, A., primary, Xu, C., additional, Roy, S., additional, Esposito, F.M., additional, Helena, O., additional, Alonso, V., additional, Yubero Esteban, A., additional, Carlos, F-M., additional, Salud Salvia, M.A., additional, Gallego Plazas, J., additional, Rodriguez Monwbray, J.R., additional, Marta, M.M-R., additional, Fernandez, J., additional, Manzano, H., additional, Aparicio, J., additional, Feliu, J., additional, and Maurel, J., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
- Author
-
Custodio, A., Moreno-Rubio, J., Aparicio, J., Gallego-Plazas, J., Yaya, R., Maurel, J., Higuera, O., Burgos, E., Ramos, D., Calatrava, A., Andrada, E., López, R., Moreno, V., Madero, R., Cejas, P., and Feliu, J.
- Published
- 2014
- Full Text
- View/download PDF
9. P-41 What to expect from best supportive care as initial approach for newly-diagnosed colorectal cancer: A single institution experience
- Author
-
Viñal, D., primary, Martinez-Recio, S., additional, Martinez Perez, D., additional, Ruiz, I., additional, Peña, J., additional, Jimenez-Bou, D., additional, Rueda-Lara, A., additional, Martin-Montalvo, G., additional, Alameda, M., additional, Palacios, M., additional, Custodio, A., additional, Gutierrez-Sainz, L., additional, Ghanem, I., additional, Feliu, J., additional, and Rodríguez-Salas, N., additional
- Published
- 2022
- Full Text
- View/download PDF
10. P-40 Clinico-pathological characteristics and outcomes of patients with early-onset colorectal cancer
- Author
-
Viñal, D., primary, Martinez-Recio, S., additional, Ruiz, I., additional, Jimenez-Bou, D., additional, Peña, J., additional, Martin-Montalvo, G., additional, Rueda-Lara, A., additional, Alameda, M., additional, Prieto, I., additional, Muñoz, A., additional, Rodriguez-Cobos, J., additional, Bustamante, P., additional, Larriba, M., additional, Ghanem, I., additional, Fernandez-Barral, A., additional, Feliu, J., additional, Barbachano, A., additional, Gonzalez-Sancho, J., additional, Burgos, A., additional, G-Pastrián, L., additional, and Rodríguez-Salas, N., additional
- Published
- 2022
- Full Text
- View/download PDF
11. P-87 Clinical score to predict recurrence in patients with stage II and III colon cancer
- Author
-
Viñal, D., primary, Martinez-Recio, S., additional, Martinez Perez, D., additional, Jimenez-Bou, D., additional, Ruiz, I., additional, Peña, J., additional, Martin-Montalvo, G., additional, Alameda, M., additional, Rueda-Lara, A., additional, Gutierrez-Sainz, L., additional, Palacios, M., additional, Custodio, A., additional, Ghanem, I., additional, Feliu, J., additional, and Rodríguez-Salas, N., additional
- Published
- 2022
- Full Text
- View/download PDF
12. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer
- Author
-
Ajani, J. A., Abramov, M., Bondarenko, I., Shparyk, Y., Gorbunova, V., Hontsa, A., Otchenash, N., Alsina, M., Lazarev, S., Feliu, J., Elme, A., Esko, V., Abdalla, K., Verma, U., Benedetti, F., Aoyama, T., Mizuguchi, H., Makris, L., and Rosati, G.
- Published
- 2017
- Full Text
- View/download PDF
13. Prediction of Chemotoxicity, Unplanned Hospitalizations and Early Death in Older Patients with Colorectal Cancer Treated with Chemotherapy
- Author
-
Feliu J, Espinosa E, Basterretxea L, Paredero I, Llabrés E, Jiménez-Munárriz B, Antonio-Rebollo M, Losada B, Pinto A, Custodio AB, Del Mar Muñoz M, Gómez-Mediavilla J, Torregrosa MD, Soler G, Cruz P, Higuera O, and Molina-Garrido MJ
- Abstract
Simple Summary Chemotoxicity, unplanned hospitalizations (Uhs) and early death (ED) are common among older patients with cancer who receive chemotherapy. Our objective was to determine factors predicting these complications. A predictive score for these three complications based on geriatric, tumor and laboratory variables was developed in a series of 215 older patients with colorectal carcinoma receiving chemotherapy. The use of this score may reliably identify patients at risk to have excessive toxicity with chemotherapy, UH or ED, thus helping to plan treatment, implement adaptive measures, and intensify follow-up. Purpose: To identify risk factors for toxicity, unplanned hospitalization (UH) and early death (ED) in older patients with colorectal carcinoma (CRC) initiating chemotherapy. Methods: 215 patients over 70 years were prospectively included. Geriatric assessment was performed before treatment, and tumor and treatment variables were collected. The association between these factors and grade 3-5 toxicity, UH and ED (
- Published
- 2022
14. Undertreatment and overtreatment in older patients treated with chemotherapy
- Author
-
Feliu J, Espinosa E, Basterretxea L, Paredero I, Llabrés E, Jiménez-Munárriz B, Antonio-Rebollo M, Losada B, Pinto A, Gironés R, Custodio AB, Muñoz MDM, Gómez-Mediavilla J, Torregrosa MD, Soler G, Cruz P, Higuera O, and Molina-Garrido MJ
- Subjects
Older patient ,Overtreatment ,Chemotherapy dose ,Chemotherapy dose, Geriatric assessment, Older patient, Overtreatment, Undertreatment ,Undertreatment ,Geriatric assessment - Abstract
Background: Inconsistent doses and schemes are commonly used in older patients receiving cancer chemotherapy. We performed this study in patients with cancer and age >_ 70 years to determine the frequency of undertreatment and overtreatment as well as factors influencing the decision to modify chemotherapy doses. Patients and Methods: Patients aged >_70 years starting new chemotherapy regimens were prospectively included in a multicentre study. The schedule and drug doses were determined by the treating oncologist. Pre chemotherapy assessment included sociodemographics, treatment details and geriatric assessment (GA) variables. Association between these factors and undertreatment (use of less intensive cancer treatment [LICT] in a fit patient) or overtreatment (use of standard cancer treatment in an unfit older patient) were examined by multivariate logistic regression. Results: Three-hundred ninety-seven patients were included, 43% of whom received LICT. If not adjusted for GA, toxicity did not differ between those receiving LICT (38%) or standard doses of chemotherapy (37%). If the dose of chemotherapy was analyzed according to the results of GA 61 (15%) patients had been undertreated and 133 (34%) had been overtreated. Undertreatment was related with increasing age and decreased renal function. Factors related with overtreatment were younger age, curative intention of treatment, prescription of G-CSF as primary prophylaxis and adequate cognitive status. Overtreated patients had more grade 3-4 toxicity than those receiving treatment adapted to fragility (42% vs 31%; p < 0.05). Conclusions: The use of chemotherapy without considering GA leads to overtreatment more commonly than undertreatment in older patients with cancer. Oncologists should take into account the results of GA to stratify patients and to avoid under or overtreatment. (c) 2020 Elsevier Ltd. All rights reserved.
- Published
- 2021
15. Grain and seed protein functionality
- Author
-
Jiménez-López, José Carlos, Priego-Poyato, S., Rodrigo-García, M., Escudero-Feliu, J., García-Costela, M., Lima Cabello, Elena, Carazo-Gallego, A., Morales-Santana, Sonia, León, Josefa, Singh, S., Singh, L., Singh, H., Sangwan, S., Abiola Oso, A., Omotayo Ashafa, A., Carneiro da Silva, A., de Freitas Barbosa, M., Bento da Silva, P., Peres de Oliveira, J., Loureiro da Silva, T., Lopes Teixeira Junior, D., de Moura Rocha, M., Daniel. I.O., Mulualem T. Kassa, Can Karaca, A., Kaur Dhaliwal, S., Salaria, P., Kaushik, P., Singh, A., Nath Raina, S., Sharma, M., Chaudhary, M., Sharma, S., Rani Rajpal, V., Elkonin, L.A., Panin, V.M., Kenzhegulov, O.A., Sarsenova, S. Kh., Adejuwon, A. O., Donova, M., Tsygankova, V. A., Obayemi, O., Verma, A. P., and Pandey, N.
- Abstract
Editado por Jiménez-López, José Carlos (CSIC)
- Published
- 2021
16. Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy
- Author
-
Feliu J, Espinosa E, Basterretxea L, Paredero I, Llabrés E, Jiménez-Munárriz B, Losada B, Pinto A, Custodio AB, Muñoz MDM, Gómez-Mediavilla J, Torregrosa MD, Cruz P, Higuera O, and Molina-Garrido MJ
- Subjects
older patient ,geriatric assessment ,risk score ,chemotherapy ,unplanned hospitalizations - Abstract
Simple Summary Unplanned hospitalizations (UHs) are common among elderly patients with cancer who receive chemotherapy. This fact decreases quality of life or performance status and increases health costs. Our objective was to determine predictive factors for UH in this population. A score based on six variables taken from geriatric assessment and chemotherapy characteristics was developed in a series of 493 elderly patients receiving chemotherapy. The use of this score may reliably identify patients at risk for UH, thus helping to plan treatment, implement adaptive measures, and set up a close follow-up schedule. Purpose: To determine the incidence of unplanned hospitalization (UH) and to identify risk factors for UH in elderly patients with cancer who start chemotherapy. Methods: In all, 493 patients over 70 years starting new chemotherapy regimens were prospectively included. A pre-chemotherapy geriatric assessment was performed, and tumor and treatment variables were collected. The association between these factors and UH was examined by using multivariable logistic regression. Score points were assigned to each risk factor. Results: During the first 6 months of treatment, 37% of patients had at least one episode of UH. Risk factors were the use of combination chemotherapy at standard doses, a MAX2 index >= 1, a Charlson comorbidity score >= 2, albumin level = 1, and weight loss >5%. Three risk groups for UH were established according to the score in all patients: 0-1: 17.5%; 2: 34%; and 3-7: 57% (p < 0.001). The area under receiver operation characteristic (ROC) curve was 0.72 (95% CI: 0.67-0.77). Conclusion: This simple tool can help to reduce the incidence of UH in elderly patients with cancer who are scheduled to initiate chemotherapy treatment.
- Published
- 2021
17. Editorial
- Author
-
Ayfantopoulou, G., Gonzalez-Feliu, J., Delibašić, Boris, Ayfantopoulou, G., Gonzalez-Feliu, J., and Delibašić, Boris
- Published
- 2021
18. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
- Author
-
Oliveres, H., Alonso-Orduna, V., Feliu, J., Fernandez Montes, A., Martin-Richard, M., Galvez Munoz, E., Ruiz-Casado, A., Yubero Esteban, A., Aparicio, J., Alcaide-Garcia, J., Gallego Plazas, J., Carmona-Bayonas, A., Fernandez Martos, C., Gallego, M.R., Manzano Alemany, H., Leno, R., Esposito, F.M., Sapena, V., and Maurel, J.
- Published
- 2023
- Full Text
- View/download PDF
19. UFT (tegafur–uracil) in rectal cancer
- Author
-
Casado, E., Pfeiffer, P., Feliu, J., González-Barón, M., Vestermark, L., and Jensen, H.A.
- Published
- 2008
- Full Text
- View/download PDF
20. Logistic requirements considering environmental sensitive demand: evidence from the French food distribution sector
- Author
-
Palacios-Argüello, L., Salomée RUEL, Gonzalez-Feliu, J., Gondran, N., École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT), Ecole Supérieure de Commerce de la Rochelle (Sup de Co La Rochelle), Groupe Sup de Co La Rochelle, Laboratoire d'économie des transports (LET), Université Lumière - Lyon 2 (UL2)-École Nationale des Travaux Publics de l'État (ENTPE)-Centre National de la Recherche Scientifique (CNRS), Environnement Ville Société (EVS), Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-École nationale supérieure d'architecture de Lyon (ENSAL)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École Nationale des Travaux Publics de l'État (ENTPE)-Université Jean Monnet [Saint-Étienne] (UJM)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Environnement, Ville, Société (EVS), École normale supérieure de Lyon (ENS de Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), École normale supérieure - Lyon (ENS Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet [Saint-Étienne] (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), and Breuil, Florent
- Subjects
environmental sensitive demand ,[INFO.INFO-MO] Computer Science [cs]/Modeling and Simulation ,Logistic requirements ,food distribution system ,[INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation - Abstract
International audience; As described in the literature, the demand characteristics could influence the food distribution configuration. The aim of this paper is to explain how these demand characteristics can be used to describe the logistic requirements for food distribution configuration. With this aim, the chosen methodological approach integrates a literature review, interviews of stakeholders involved in the distribution system and a survey to the French industrial sector. Results describe the logistic requirements from for food distribution found in the literature review according to the different actors, products and distribution configuration adopted. Furthermore, the logistic requirements extracted from the literature review are compared with the primary data collected to establish the main logistic requirements linked to the conscious demand in the food supply chain for the food distribution configuration. The main logistic requirements defined are linked to facility location, supplier selection and distribution optimization due to the logistic platforms and transportation strategies development. Finally, the results of this research provide information to food supply chain actors when designing the food distribution circuits aiming to answer to conscious demand characteristics that are emerging.
- Published
- 2020
21. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients
- Author
-
Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C, and Molina-Garrido MJ
- Subjects
Elderly ,Support treatments ,Toxicity ,Chemotherapy ,Cancer - Abstract
The elderly form a very heterogeneous group in relation to their general health state, degree of dependence, comorbidities, performance status, physical reserve and geriatric situation, so cancer treatment in the older patient remains a therapeutic challenge. The physiological changes associated with aging increase the risk of developing a serious toxicity induced by chemotherapy treatment, as well as other undesirable consequences as hospitalizations, dependence and non-compliance with treatment, that can negatively affect survival, quality of life and treatment efficacy. The use of hematopoietic growth factors and other active supportive interventions in the elderly can help prevent and/or alleviate these toxicities. However, we have little data on the efficacy and tolerance of support treatments in the older patient. The objective of this work is to review the most frequent toxicities of oncological treatments in the elderly and their management.
- Published
- 2020
22. Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study
- Author
-
Feliu J, Jiménez-Munárriz B, Basterretxea L, Paredero I, Llabrés E, Antonio-Rebollo M, Losada B, Espinosa E, Gironés R, Custodio AB, Muñoz MDM, Díaz-Almirón M, Gómez-Mediavilla J, Pinto A, Torregrosa MD, Soler G, Cruz P, Higuera O, and Molina-Garrido MJ
- Subjects
Toxicity risk score ,Older patient ,Toxicity ,Chemotherapy ,Geriatric assessment - Abstract
Background Standard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy-related complications. Materials and Methods Patients over 70 years of age starting new chemotherapy regimens were prospectively included in a multicenter study. A prechemotherapy assessment that included sociodemographics, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and the development of grade 3-5 toxicity was examined by using logistic regression. Results A total of 551 patients were accrued. Chemotherapy doses (odds ratio [OR] 1.834; 95% confidence interval [CI] 1.237-2.719) and creatinine clearance (OR 0.989; 95% CI 0.981-0.997) were the only factors independently associated with toxicity. Only 19% of patients who received reduced doses of chemotherapy and had a creatinine clearance >= 40 mL/minute had grade 3-4 toxicity, compared with 38% of those who received standard doses or had a creatinine clearance
- Published
- 2020
23. Narrow-leafed lupin (Lupinus angustifolius L.) seed ß-conglutin proteins induce G0/G1 arrest and apoptosis in human colorectal cancer cells
- Author
-
García-Costela, M., Escudero-Feliu, J., Ríos-Arrabal, S., Moreno-SanJuan, J.D., Puentes-Pardo, J.D., León, J., Jiménez-López, José Carlos, European Commission, Ministerio de Economía y Competitividad (España), and Consejo Superior de Investigaciones Científicas (España)
- Abstract
1 página de abstract y Poster presentado en IV Congreso Nacional de Jóvenes Investigadores en Biomedicina (IV National Congress of Young Researchers in Biomedicine) Celebrado en Granada, España. 4-6 nov 2020, Supported by European Research Program MARIE CURIE (FP7-PEOPLE-2011-IOF), Project ref.: PIOF-GA-2011-301550; by the Spanish Government (MINECO), project ref.: RYC-2014-16536 (Research Program Ramon y Cajal), and project ref.: BFU2016- 77243-P; and by CSIC – Intramural project, Ref: 201540E065
- Published
- 2020
24. Seed Beta-conglutin proteins from narrow-leafed lupin (Lupinus angustifolius l.) as functional foods and their role in cancer prevention
- Author
-
Escudero-Feliu, J., García-Costela, M., Morales-Santana, Sonia, Ríos-Arrabal, S., Núñez, M.I., León, J., Jiménez-López, José Carlos, European Commission, Ministerio de Economía y Competitividad (España), and Instituto de Salud Carlos III
- Abstract
1 página.- Presentacion oral en el 25th National Symposium for Applied Biological Sciences (NSABS). Celebrado en Gembloux, Belgica. 31 enero 2020, European Research Program MARIE CURIE (FP7-PEOPLE-2011-IOF), Project ref.: PIOFGA2011-301550; The Spanish Government (MINECO), project ref.: RYC-2014-16536 (Ramon y Cajal Research Program); and project ref.: BFU2016-77243-P; CSIC – Intramural project ref.: 201540E065; and Institute of Health Carlos III, project ref.: PIE16/00045 (ISCIII).
- Published
- 2020
25. P-302 Survival impact of fluoropyrimidine dose adjustment in DPD deficient colorectal cancer patients: A single center experience
- Author
-
Perez, D. Martinez, Ghanem, I., Peña, J., Ruiz-Gutierrez, I., Jimenez-Bou, D., Viñal, D., Custodio, A., Feliu, J., and Rosas, R.
- Published
- 2023
- Full Text
- View/download PDF
26. P-279 Adjuvant chemotherapy for patients with stage III colon cancer, three months vs six months. A single centre experience
- Author
-
Martin-Montalvo, G., Perez, D. Martinez, Ruiz-Gutierrez, I., Alameda, M., Rueda-Lara, A., Peña, J., Jimenez-Bou, D., Viñal, D., Garcia-Cuesta, J., Barbas, J. Pedregosa, Rodríguez-Salas, N., and Feliu, J.
- Published
- 2023
- Full Text
- View/download PDF
27. P-265 Value of the Glasgow Prognostic Score (GPS) in the prognosis of hospitalised patients with gastrointestinal cancer
- Author
-
Peña, J., Rueda-Lara, A., Martin-Montalvo, G., Alameda, M., Jimenez-Bou, D., Ruiz-Gutierrez, I., Marcano, R., Garcia-Leal, A., Contreras, P. Zwisler, Perez, D. Martinez, Viñal, D., Perez-Wert, J., Custodio, A., Ghanem, I., Rodríguez-Salas, N., Feliu, J., Ruiz-Giménez, L., and Sanchez, D.
- Published
- 2023
- Full Text
- View/download PDF
28. P-261 Oxaliplatine plus fluoropyrimidine versus fluoropyrimidine monotherapy as adjuvant treatment for stage III resected colorectal cancer (CRC) in older population, a single centre experience
- Author
-
Ruiz-Gutierrez, I., Jimenez-Bou, D., Peña, J., Perez, D. Martinez, Martinez-Recio, S., Viñal, D., Alameda, M., Martin-Montalvo, G., Rueda-Lara, A., Garcia-Cuesta, J., Barbas, J. Pedregosa, Marcano, R., Garcia-Leal, A., Contreras, P. Zwisler, Perez-Wert, J., Custodio, A., Ghanem, I., Rodríguez-Salas, N., and Feliu, J.
- Published
- 2023
- Full Text
- View/download PDF
29. P-242 Characterisation of KRAS mutations in patients with metastatic colorectal cancer: A single institution experience
- Author
-
Alameda, M., Rueda-Lara, A., Viñal, D., Contreras, P. Zwisler, Martin-Montalvo, G., Ruiz-Gutierrez, I., Peña, J., Jimenez-Bou, D., Perez, D. Martinez, Barbas, J. Pedregosa, Garcia-Cuesta, J., Rodríguez-Salas, N., Feliu, J., Rios, M., and Mendiola, M.
- Published
- 2023
- Full Text
- View/download PDF
30. P-222 Prognostic value of skeletal muscle area at diagnosis in patients with metastatic colorectal cancer: A single institution experience
- Author
-
Rios, M., Viñal, D., Rueda-Lara, A., Alameda, M., Martin-Montalvo, G., Rodríguez-Salas, N., and Feliu, J.
- Published
- 2023
- Full Text
- View/download PDF
31. Formic acid oxidation on Pd-modified Pt(100) and Pt(111) electrodes: A DEMS study
- Author
-
Vidal-Iglesias, F. J., Solla-Gullón, J., Herrero, E., Aldaz, A., and Feliu, J. M.
- Published
- 2006
- Full Text
- View/download PDF
32. Acknowledgement to reviewers of social sciences in 2019
- Author
-
Abbas, A., Abel, G., Abreu, A., Adam, A., Adamek, M., Adiletta, G., Adusei-asante, K.A., Romeo, M.D.M., Alderson, A., Alfaro, E., Aliverti, A., Almeida, Fernando, Álvarez-gonzález, L.I., Amelina, A., Anand, C., Anderson, G., Andreasson, J., Ang, I., Aragon, J., Arcidiacono, C., Arcuri, S., Assante, D., Atukeren, E., Avery, H., Ayeb-karlsson, S., Azadi, H., Bachman, R., Bader, M., Badulescu, A., Bahmanteymouri, E., Baines, S., Baker, T., Baker‐beall, C., Bañón, L., Bar‐am, N., Barbier‐greenland, K., Barnett, R., Barragán‐escandón, A., Barreto, A.M., Barrett, E., Bartkowski, J., Bartram, R., Bartzas, G., Bates, D., Baviera‐puig, A., Bayley, A., Beazley, H., Beer, C., Behr, H., Beier, G., Belford, N., Bencivenga, R., Benli, A.E., Benton‐short, L., Berei, J.M., Berbel‐pineda, E., Bernstein, Berntzen, E.R., Bertella, L., Birney, G., Bittle, M., Black, S., Rivero, L.B., Blattner, J.J., Blok, C., Blount, A., Boas, Y., Bockarie, I., Bockerman, A., Bodén, P., Bönisch‐brednich, L., Bontje, B., Bontje, M., Borsellino, V., Bostan, I., Bowl, M., Bowman, B., Bracci, E., Bracken, C.M., Bradley, H., Brereton, P., Brewer, J., Bridge, D., Brooks, S., Brown, Andrijana, Brzoska, M., Brzozowski, W., Buckley, G., Buente, W., Bullaro, G.R., Burke, M.D., Burlacu, S., Busu, M., Butler, S., Byrne, J., Cabral, L., Cai, Y., Cajias, M., Calin, A.C., Callegari, C., Camarero, M., Campbell-figuerola, H., Campbell, J.R., Cannito, M., Canonico, E., Canosa, A., Carabelli, G., Carlbom, A., Carlone, T., Caron, R., Carpenter, A., Caruso, G., Casais, B., Castro, M.P., Cava, M.-J., Čeněk, J., Cerchione, R., Certomà, C., Chan, E., Charles, D., Charlwood, A., Chatzifotiou, S., Chell, K., Chen, L., Chen, Q., Chen, W.-J., Ching, L., Christensen, J., Ciasullo, M.V., Cimermanová, I., Činčera, J., Cipollina, M., Clutterbuck, R., Cochrane, B., Collin, K., Conley, R., Connell, H., Connelly, J., Connelly, L., Connelly, R., Conti, D., Conversi, D., Conway, G., Cooper, S., Cope, M., Corsini, F., Cristian, P., Crohn, H.M., Croog, R.C., Salazar, T., Csiszár, C., D’auria, I., D’souza, A., D’souza, N., Dabija, D.-C., Dagg, J., Dalby, S., DaleDalsgård, B., Dʹamato, A.L., Daniel, D., Dant, L., Dantas, C., Darwin, H., Dashper, K., David, M.E., De Flippo, D., De, A., Edi, M., Velázquez, E.D.C., Velázquez, F., Del Vecchio, P., Delatolla, A., Delgado, P., Delgado‐romero, E., Delrosso, J., Desimone, J., Detlefsen, L., Devaney, C., Díaz, L.M., Didham, R., Diogo, E., Dirakis, A., Doberneck, D., Doidge, M.D., Molero, G., Dombrowski, P.J., Doñate, C., Đorđević, Martín, Reis, P.G.R., Doucek, P., Dundes, L., Dvouletý, O., Dybo, T., Eastman, J., Eckhardt, J., Economou, A., Edler, D., Edu, U., Ekblom, P.E., Khaled, D., Ellis, C., Elsabry, E., Erceg, A., Erokhin, V., Ertz, M., Everitt, J., Evers, A., Falcone, P.M.F., Cabana, P., Fawcett, B., Fearnley, B., Featherstone, M., Ferreira, M., Ferreira, P., Fetner, T., Fisher, J., Fisher, R., Fitzpatrick, T., Flanagan, C., Fogarty, E.A., Fonchingong, C.C., Fontana, M., Fook, J., Foreman, A.M., Foster‐mcgregor, N., Fox, S., Franco, J.A., Franklin, A.L., Friedrich, T., Fromm, I., Fu, N., Fucà, R., Fukuda, Y., Fusco, G., Gabriela, D., Galan, D., Gamo, A., Galiano, J., Garcia, A., García, M.E.A., García‐germán, S., García‐machado, J.J., García‐ruiz, C.R., Gavini, M., Gazzano, A., Gebhardt, M., Gerson, S., Gherghina, Ş.C., Gibbs, P., Gilhooly, D., Gill, F., Gill, N., Gil‐lopez, A.J., Ginès Fabrellas, A., Giuffrida, N., Giuliani, G., Goddard, J., Godderis, R., Goh, C.S., Gomes, O., Goncharuk, A.G., Canche, M.G., Pérez, I.G., Valero, G., González, R.C.L., Gonzalez‐benson, O., Gonzalez‐feliu, J., González‐lópez, M., Gozdziak, E., Granx, B., Gran, R., Gray, S.L., Grbes, A., Grondys, K., Grugan, S., Guenther, J., Guijarro, F., Gurko, T., Haas, L.L., Hagellx, A., Hagell, H., Hallgrímsdóttir, H., Hamada, T., Hanf, J., Hannouf, M., Hao, F., Harman, G., Harris, K.L., Harris, R., Harrison, N.H., Healy, G., Healy, K., Heikkilä, E., Hellmich, C., Henig, J., Henninger, C.E., Heo, W., Herman, C., Herrero‐diz, P., Heyman, J., Hibbert, N., Hillman, A.L., Hillman, B., Hine, B., Hino, K., Hinten, M., Hipp, L., Hoang, D., Holleran, D., Hollin, I., Holm, M., Holmes, C., Hook, G., Hoornweg, D., Hopper, L., Hossain, M., Hoxhaj, R., Hu, B., Huang, Y., Huarita, E., Hudec, O., Humbert, A.L., Hung, M.-C., Hunt, A., Husu, L., IanoleIbáñez‐gonzález, R., Ibáñez‐gonzález, M.J., Ide, T., Ijaz, Muhammad Fazal, Impicciatore, R., Ingwersen, M., Ioannides, D., Iseppi, L., Islam, M.M., Jaakkola, M., Jagger, S., Jagosh, J., Jenkin, G., Joelsson, T., Johansen, R.E.B., Johnsen, H.C., Garmann Jona, G., Jones, T., Judit, O., Kalalahti, M., Kang, M., Kantamaneni, K., Kaplan, L., Kapsalis, V., Karbowski, A., Katsoni, V., Kavish, D.R., Kawamura, H., Keilman, N.W., Kelly, J., Kenneth, H., Kepaptsoglou, K., Kevin, D., Kewley, S., Kim, J.-C., Kim, K.-Y., Kim, S., Kimengsi, J.N., Klein, J., Kleine, M., Klemes, J.I.R.I., Klepp, S., Klinkenberg, L.E.F., Knight, L., Knowles, J., Koerner, S., Konsolakis, K., Konstantinov, V., Kopkin, N.K., Kordova, S., Kosinski, E., Kostelka, F., Kot, S., Kotter, R., Kramers, A., Krienert, J.L., Kubon, M., Kuffer, M., Kungolos, A., Kuttner, P., Kużelewska, E., Ladd, A.E., Lammi, M., Landrum, J., Lange, B., Languilaire, T.D., Lantz, J.-C., Laudal, B., Laurentsyeva, T., Lavizzari, N., Lavoie, A., Feuvre, J.L., Leakey, N., Lee, R., Lee, A., Lee, E., Lee, J., Lentner, J.-H., Lenz‐taguchi, C., Leong, H., Levac, W.S., Lewin, L., Lewinson, E., Li, T., Li, F., Li, G., Li, M., Liczmańska‐kopcewicz, Y., Lillard, K., Linková, C., Links, M., Lipinski, P., Storto, J.L., Lochtman, C., Lockwood, K., Loh, A., Lomonaco‐benzing, V., Łopaciuk‐gonczaryk, R., López, B., lópez, D., Lorenzini, J., Löther, A., Loughnan, C., Love, T., Lucas, M.L., Ubago, J., Lukić, J., Lumley‐sapanski, A., Macedo, I., Macfarlane, S., Machimbarrena, J.M., Magda, R., Magrane, D., Maier, D., Majić, S., Majumdar, S., Makarovič, M., Malekigorji, M., Mallick, B., Malone, D., Mandić, D., Maniou, T., Mannell, J.M., Barbutiu, S., Marczak, M., Markvica, K.M., Aragón, M.D.M., Martín, J.S.M., Pereira, A., Marzal‐felici, J., Mason, F., Mather, J., Matijosaitiene, I., MatthewsMattisson, R., Mattisson, C., Matuszak, Ł., Matuzeviciute, K., Mauerer, G., Mayer, A., McCaig, C., McClearn, D., McKee, S.C., McKendry, S., McMahon, M., McReynolds, P., Medina‐vicent, M., Medyna, G., Mees, H., Meil, G., Meringolo, P., Miciuła, I., Milczarek‐andrzejewska, D., Miles, P., Milivojević, S., Miller, G., Minello, A., Miron, D., Mironeasa, S., Misra, J., Mitchell, T., Moldovan, O., Molero, P.P., Møllersen, S., Momsen, J.H., Moniz, A.B., Morea, D., Moreau, M.-P., Morgan, D.L., Morgan, H., Moscatelli, S., Mostowska, M., Mousavi, A., Mousavi, S., Mrugalska, B., Muinos, G., Mukungu, K., Mukuni, J., Murakami, D., Muresan, I.C., Murib, Z., Muro, A., Mustafa, G., Nackerud, L., Nalmpantis, D., Napal, M., Närvi, J., Naser, M., Nash, V., Navarre‐jackson, L., Navarro, R., Nazarczuk, D., Neale, J., Necula, J., Němec, S., Neven, D., Nevgi, A., Newbold, A., Newton, G., New, A., Niakšu, O., Niiniluoto, I., Nkogo, J.C., Nobre, S., Nunn, P., Oakes, R., Obrad, C., Oke, A., Okorie, O., Oncioiu, I., Ormsbee, F., Ortega‐sánchez, D., Osgood, J., Osorio, C., Oswald, J., Otis, M.D., Ouassini, A., Oxford, S., Page, T., Paixão, M.J., De Pajares, E.M., Palmesr, E., Palos‐sánchez, P., Pamučar, Dragan, Pan, H., Panek, J., Pankowska, M., Papadakis, S., Papafilippou, V.P., Medina, R., Park, C.S., Partalidou, M., Passantino, A., Passini, S., Paul, S., Pavliuk, R., Pearce, P., Pease, K., Pentaris, P., Perez, V.W., Pérez‐armendáriz, C., Perez‐vaisvidovsky, N., Perez‐y‐perez, M., Perry, N., Prtchu, D., Peterson, D.A.M., Alexandru‐ionut, Petrykowski, Petrykowski, P., Phillips, L., Pickard, S., Pickel, A., Pieke, F., Piekut, A., Pierce, S., Pierrakis, Y., Piguet, E., Pleace, N., Połom, M., Polsa, P., Ponticorvo, M., Pookulangara, S., Pope, J., Popoli, P., Postigo, J.C., Price‐Wolf, J., Prior, S., Privitera, D., Prud’homme, C., Prosser, J., Prus, P., Puiu, S., Purcell, R., Pyrialakou, D., Quam‐wickham, N., Quarmby, T., Quinlan, K.M., Quinn, A., Quinn, R., Raciti, M., Radicić, D., Rahimi, B., Ramlo, S., Randle, H., Ratajczak, M., Raymond, T., Recio‐menéndez, M., Reese, L.A., Regner, T., Reichman, J., WReim, iebke, R., Pastor, A.M., Rexhepi, G., Reyes‐menendez, A., Reynaud, C., Ribeiro‐soriano, D., Ricci, S., Ridaura, G., Rita, C., Roberts, M., Roberts, G., Roberts, K., Rockerbie, D., Rodger, J.A., Rodin, G., Rodrigues, D.R., Martín, J.A., Rodríguez, C.F., Rodriguez‐modroño, P., Romero‐rodríguez, L.M., Rončáková, T., Roper, I., Rorie, M.R., Marzán, C.F., Rose, G., Rose, M., Rosen, R., Roth, R., Roubík, H., Roumpos, C., Rowbottom, D., Roy, J., Ruban, D., Rubira‐garcía, R., Ruiperez‐valiente, J.A., Ruiz, R., Ruiz‐real, J.L., Russell, B., Russo, K., Sabol, W., Safonte, F., Salin, M., Salom‐carrasco, J.S., Sánchez, L.D., Sanghera, Santos, B.S., Silva, D., Sanz, F., Sanz‐altamira, B., Sarapura, S., Sari, D., Satybaldieva, E., Saura, J.R., Sayed, N., Scandurra, C., Schartner, A., Schellekens, J., Schenk‐hoppé, K.R., Scherer, L., Schewe, J.A., Schewe, R., Schiller, N.G., Schmidt, E.-M., Schneickert, C., Schneider, J., Scott, H., Scott, P., Seibel, K., Seidler, R., Seifert, S.S., Puyuelo, M.S., Azevedo, P.S., Lopez, A.E.S., Raamkumar, A.S., Blundo, D., Severo, M., Shakya, K.M., Shapiro, A., Shaw, I.F., Shaw, T.V., Shea, B., Shearer, H., Sheldon, S., Shell‐duncan, B., Shepherd, S., Sheridan, L., Siemienska, R., Sillup, G.P., Simeon, J.C., Simonelli, A., Skilodimou, H.D., Škrinjarić, T., Slater, G., Smardon, R., Smith, J., Smoląg, K., Snauwaert, D.T., Soanes‐white, T., Sobocińska, M., Sohaib, O., Soldatić, K., Sorainen, G.T., Soldatos, A., Sørensen, N.N., Spanu, S., Stadlober, E., Stafford, F., Ștefănescu‐mihăilă, R.O., Stefanini, A., Štefko, R., Steglich, E., Steirer, G., Stephenson, M.O., Stoecker, R., Stoffelen, A., Strang, A., Suppa, D., Sutton, J., Svobodová, L., Swigon, M., Synnott, J., Sytsma, V., Tabe, T., Tajeddini, K., Tang, S., Taylor, B., Taylor, C., Teignier, M., Teixeira, C., Tempelaar, D., Ter Avest, K.H., Ter Horst, E., Testa, M.R., Thakur, N., Thiamwong, L., Thijsen, A., Thomas, B.A., Thompson, C., Thompson, D., Tisdall, K., Toft, Mancini, Torell, A., Toscano‐hernández, G., Tregua, A.E., Triandafyllidou, M., Tseloni, A., Seloni, A., Tsikouras, P., Tsogas, G., Twamley, K., Tyler, D.U., Haque, A., Underwood, M., Urbański, M., Uribe‐toril, J., Vaezipour, A., Van Hove, L.V., Huylenbroeck, G., Van Nuland, S., Vanner, C., Vázquez‐cano, E., Veen, E., Veintimilla, S.G.-A., Veković, M., Velija, P., Venco, E.M., Verticelli, A., Vicente, P.V., Estiarte, C., Višnjić, A., Visvizi, A., Vlasblom, J.D., Volsche, S.V., Fintel, D., Von Keyserlingk, L., Vranješević, J., Walter, K.V., Wandosell, G., Wang, Y., Wasileski, G., Wastl‐walter, D., Weaving, C., Weenik, D., Wehr, K., Wei, X., Wharton, A., White, G., Whitehouse, H., Whitley, C.T., Whitman, L., Wiersma‐mosley, J.D., Wilcke, H., Wilkes, R., Williams, L., Williamson, R.D., Wimalasena, L., Wiseman, A., Wołek, M., Wright, E.Q., Wroblewski, A., Wyile, A.S., Wynn, C., Xu, X., Xue, B., Yang, J., Yoe, T.M., Young, M., Younus, M., Yu, T.-F., Yuan, Q., Zadra, C., Zaharijević, A., Zajda, J., Zander, K., Zbuchea, A., Zelin, A., Zhang, C., Zippel, K., Zitricky, V., Živanović, P., Zou, L., Zufferey, C., Zuhdi, M., Zumeta, W.M., Abbas, A., Abel, G., Abreu, A., Adam, A., Adamek, M., Adiletta, G., Adusei-asante, K.A., Romeo, M.D.M., Alderson, A., Alfaro, E., Aliverti, A., Almeida, Fernando, Álvarez-gonzález, L.I., Amelina, A., Anand, C., Anderson, G., Andreasson, J., Ang, I., Aragon, J., Arcidiacono, C., Arcuri, S., Assante, D., Atukeren, E., Avery, H., Ayeb-karlsson, S., Azadi, H., Bachman, R., Bader, M., Badulescu, A., Bahmanteymouri, E., Baines, S., Baker, T., Baker‐beall, C., Bañón, L., Bar‐am, N., Barbier‐greenland, K., Barnett, R., Barragán‐escandón, A., Barreto, A.M., Barrett, E., Bartkowski, J., Bartram, R., Bartzas, G., Bates, D., Baviera‐puig, A., Bayley, A., Beazley, H., Beer, C., Behr, H., Beier, G., Belford, N., Bencivenga, R., Benli, A.E., Benton‐short, L., Berei, J.M., Berbel‐pineda, E., Bernstein, Berntzen, E.R., Bertella, L., Birney, G., Bittle, M., Black, S., Rivero, L.B., Blattner, J.J., Blok, C., Blount, A., Boas, Y., Bockarie, I., Bockerman, A., Bodén, P., Bönisch‐brednich, L., Bontje, B., Bontje, M., Borsellino, V., Bostan, I., Bowl, M., Bowman, B., Bracci, E., Bracken, C.M., Bradley, H., Brereton, P., Brewer, J., Bridge, D., Brooks, S., Brown, Andrijana, Brzoska, M., Brzozowski, W., Buckley, G., Buente, W., Bullaro, G.R., Burke, M.D., Burlacu, S., Busu, M., Butler, S., Byrne, J., Cabral, L., Cai, Y., Cajias, M., Calin, A.C., Callegari, C., Camarero, M., Campbell-figuerola, H., Campbell, J.R., Cannito, M., Canonico, E., Canosa, A., Carabelli, G., Carlbom, A., Carlone, T., Caron, R., Carpenter, A., Caruso, G., Casais, B., Castro, M.P., Cava, M.-J., Čeněk, J., Cerchione, R., Certomà, C., Chan, E., Charles, D., Charlwood, A., Chatzifotiou, S., Chell, K., Chen, L., Chen, Q., Chen, W.-J., Ching, L., Christensen, J., Ciasullo, M.V., Cimermanová, I., Činčera, J., Cipollina, M., Clutterbuck, R., Cochrane, B., Collin, K., Conley, R., Connell, H., Connelly, J., Connelly, L., Connelly, R., Conti, D., Conversi, D., Conway, G., Cooper, S., Cope, M., Corsini, F., Cristian, P., Crohn, H.M., Croog, R.C., Salazar, T., Csiszár, C., D’auria, I., D’souza, A., D’souza, N., Dabija, D.-C., Dagg, J., Dalby, S., DaleDalsgård, B., Dʹamato, A.L., Daniel, D., Dant, L., Dantas, C., Darwin, H., Dashper, K., David, M.E., De Flippo, D., De, A., Edi, M., Velázquez, E.D.C., Velázquez, F., Del Vecchio, P., Delatolla, A., Delgado, P., Delgado‐romero, E., Delrosso, J., Desimone, J., Detlefsen, L., Devaney, C., Díaz, L.M., Didham, R., Diogo, E., Dirakis, A., Doberneck, D., Doidge, M.D., Molero, G., Dombrowski, P.J., Doñate, C., Đorđević, Martín, Reis, P.G.R., Doucek, P., Dundes, L., Dvouletý, O., Dybo, T., Eastman, J., Eckhardt, J., Economou, A., Edler, D., Edu, U., Ekblom, P.E., Khaled, D., Ellis, C., Elsabry, E., Erceg, A., Erokhin, V., Ertz, M., Everitt, J., Evers, A., Falcone, P.M.F., Cabana, P., Fawcett, B., Fearnley, B., Featherstone, M., Ferreira, M., Ferreira, P., Fetner, T., Fisher, J., Fisher, R., Fitzpatrick, T., Flanagan, C., Fogarty, E.A., Fonchingong, C.C., Fontana, M., Fook, J., Foreman, A.M., Foster‐mcgregor, N., Fox, S., Franco, J.A., Franklin, A.L., Friedrich, T., Fromm, I., Fu, N., Fucà, R., Fukuda, Y., Fusco, G., Gabriela, D., Galan, D., Gamo, A., Galiano, J., Garcia, A., García, M.E.A., García‐germán, S., García‐machado, J.J., García‐ruiz, C.R., Gavini, M., Gazzano, A., Gebhardt, M., Gerson, S., Gherghina, Ş.C., Gibbs, P., Gilhooly, D., Gill, F., Gill, N., Gil‐lopez, A.J., Ginès Fabrellas, A., Giuffrida, N., Giuliani, G., Goddard, J., Godderis, R., Goh, C.S., Gomes, O., Goncharuk, A.G., Canche, M.G., Pérez, I.G., Valero, G., González, R.C.L., Gonzalez‐benson, O., Gonzalez‐feliu, J., González‐lópez, M., Gozdziak, E., Granx, B., Gran, R., Gray, S.L., Grbes, A., Grondys, K., Grugan, S., Guenther, J., Guijarro, F., Gurko, T., Haas, L.L., Hagellx, A., Hagell, H., Hallgrímsdóttir, H., Hamada, T., Hanf, J., Hannouf, M., Hao, F., Harman, G., Harris, K.L., Harris, R., Harrison, N.H., Healy, G., Healy, K., Heikkilä, E., Hellmich, C., Henig, J., Henninger, C.E., Heo, W., Herman, C., Herrero‐diz, P., Heyman, J., Hibbert, N., Hillman, A.L., Hillman, B., Hine, B., Hino, K., Hinten, M., Hipp, L., Hoang, D., Holleran, D., Hollin, I., Holm, M., Holmes, C., Hook, G., Hoornweg, D., Hopper, L., Hossain, M., Hoxhaj, R., Hu, B., Huang, Y., Huarita, E., Hudec, O., Humbert, A.L., Hung, M.-C., Hunt, A., Husu, L., IanoleIbáñez‐gonzález, R., Ibáñez‐gonzález, M.J., Ide, T., Ijaz, Muhammad Fazal, Impicciatore, R., Ingwersen, M., Ioannides, D., Iseppi, L., Islam, M.M., Jaakkola, M., Jagger, S., Jagosh, J., Jenkin, G., Joelsson, T., Johansen, R.E.B., Johnsen, H.C., Garmann Jona, G., Jones, T., Judit, O., Kalalahti, M., Kang, M., Kantamaneni, K., Kaplan, L., Kapsalis, V., Karbowski, A., Katsoni, V., Kavish, D.R., Kawamura, H., Keilman, N.W., Kelly, J., Kenneth, H., Kepaptsoglou, K., Kevin, D., Kewley, S., Kim, J.-C., Kim, K.-Y., Kim, S., Kimengsi, J.N., Klein, J., Kleine, M., Klemes, J.I.R.I., Klepp, S., Klinkenberg, L.E.F., Knight, L., Knowles, J., Koerner, S., Konsolakis, K., Konstantinov, V., Kopkin, N.K., Kordova, S., Kosinski, E., Kostelka, F., Kot, S., Kotter, R., Kramers, A., Krienert, J.L., Kubon, M., Kuffer, M., Kungolos, A., Kuttner, P., Kużelewska, E., Ladd, A.E., Lammi, M., Landrum, J., Lange, B., Languilaire, T.D., Lantz, J.-C., Laudal, B., Laurentsyeva, T., Lavizzari, N., Lavoie, A., Feuvre, J.L., Leakey, N., Lee, R., Lee, A., Lee, E., Lee, J., Lentner, J.-H., Lenz‐taguchi, C., Leong, H., Levac, W.S., Lewin, L., Lewinson, E., Li, T., Li, F., Li, G., Li, M., Liczmańska‐kopcewicz, Y., Lillard, K., Linková, C., Links, M., Lipinski, P., Storto, J.L., Lochtman, C., Lockwood, K., Loh, A., Lomonaco‐benzing, V., Łopaciuk‐gonczaryk, R., López, B., lópez, D., Lorenzini, J., Löther, A., Loughnan, C., Love, T., Lucas, M.L., Ubago, J., Lukić, J., Lumley‐sapanski, A., Macedo, I., Macfarlane, S., Machimbarrena, J.M., Magda, R., Magrane, D., Maier, D., Majić, S., Majumdar, S., Makarovič, M., Malekigorji, M., Mallick, B., Malone, D., Mandić, D., Maniou, T., Mannell, J.M., Barbutiu, S., Marczak, M., Markvica, K.M., Aragón, M.D.M., Martín, J.S.M., Pereira, A., Marzal‐felici, J., Mason, F., Mather, J., Matijosaitiene, I., MatthewsMattisson, R., Mattisson, C., Matuszak, Ł., Matuzeviciute, K., Mauerer, G., Mayer, A., McCaig, C., McClearn, D., McKee, S.C., McKendry, S., McMahon, M., McReynolds, P., Medina‐vicent, M., Medyna, G., Mees, H., Meil, G., Meringolo, P., Miciuła, I., Milczarek‐andrzejewska, D., Miles, P., Milivojević, S., Miller, G., Minello, A., Miron, D., Mironeasa, S., Misra, J., Mitchell, T., Moldovan, O., Molero, P.P., Møllersen, S., Momsen, J.H., Moniz, A.B., Morea, D., Moreau, M.-P., Morgan, D.L., Morgan, H., Moscatelli, S., Mostowska, M., Mousavi, A., Mousavi, S., Mrugalska, B., Muinos, G., Mukungu, K., Mukuni, J., Murakami, D., Muresan, I.C., Murib, Z., Muro, A., Mustafa, G., Nackerud, L., Nalmpantis, D., Napal, M., Närvi, J., Naser, M., Nash, V., Navarre‐jackson, L., Navarro, R., Nazarczuk, D., Neale, J., Necula, J., Němec, S., Neven, D., Nevgi, A., Newbold, A., Newton, G., New, A., Niakšu, O., Niiniluoto, I., Nkogo, J.C., Nobre, S., Nunn, P., Oakes, R., Obrad, C., Oke, A., Okorie, O., Oncioiu, I., Ormsbee, F., Ortega‐sánchez, D., Osgood, J., Osorio, C., Oswald, J., Otis, M.D., Ouassini, A., Oxford, S., Page, T., Paixão, M.J., De Pajares, E.M., Palmesr, E., Palos‐sánchez, P., Pamučar, Dragan, Pan, H., Panek, J., Pankowska, M., Papadakis, S., Papafilippou, V.P., Medina, R., Park, C.S., Partalidou, M., Passantino, A., Passini, S., Paul, S., Pavliuk, R., Pearce, P., Pease, K., Pentaris, P., Perez, V.W., Pérez‐armendáriz, C., Perez‐vaisvidovsky, N., Perez‐y‐perez, M., Perry, N., Prtchu, D., Peterson, D.A.M., Alexandru‐ionut, Petrykowski, Petrykowski, P., Phillips, L., Pickard, S., Pickel, A., Pieke, F., Piekut, A., Pierce, S., Pierrakis, Y., Piguet, E., Pleace, N., Połom, M., Polsa, P., Ponticorvo, M., Pookulangara, S., Pope, J., Popoli, P., Postigo, J.C., Price‐Wolf, J., Prior, S., Privitera, D., Prud’homme, C., Prosser, J., Prus, P., Puiu, S., Purcell, R., Pyrialakou, D., Quam‐wickham, N., Quarmby, T., Quinlan, K.M., Quinn, A., Quinn, R., Raciti, M., Radicić, D., Rahimi, B., Ramlo, S., Randle, H., Ratajczak, M., Raymond, T., Recio‐menéndez, M., Reese, L.A., Regner, T., Reichman, J., WReim, iebke, R., Pastor, A.M., Rexhepi, G., Reyes‐menendez, A., Reynaud, C., Ribeiro‐soriano, D., Ricci, S., Ridaura, G., Rita, C., Roberts, M., Roberts, G., Roberts, K., Rockerbie, D., Rodger, J.A., Rodin, G., Rodrigues, D.R., Martín, J.A., Rodríguez, C.F., Rodriguez‐modroño, P., Romero‐rodríguez, L.M., Rončáková, T., Roper, I., Rorie, M.R., Marzán, C.F., Rose, G., Rose, M., Rosen, R., Roth, R., Roubík, H., Roumpos, C., Rowbottom, D., Roy, J., Ruban, D., Rubira‐garcía, R., Ruiperez‐valiente, J.A., Ruiz, R., Ruiz‐real, J.L., Russell, B., Russo, K., Sabol, W., Safonte, F., Salin, M., Salom‐carrasco, J.S., Sánchez, L.D., Sanghera, Santos, B.S., Silva, D., Sanz, F., Sanz‐altamira, B., Sarapura, S., Sari, D., Satybaldieva, E., Saura, J.R., Sayed, N., Scandurra, C., Schartner, A., Schellekens, J., Schenk‐hoppé, K.R., Scherer, L., Schewe, J.A., Schewe, R., Schiller, N.G., Schmidt, E.-M., Schneickert, C., Schneider, J., Scott, H., Scott, P., Seibel, K., Seidler, R., Seifert, S.S., Puyuelo, M.S., Azevedo, P.S., Lopez, A.E.S., Raamkumar, A.S., Blundo, D., Severo, M., Shakya, K.M., Shapiro, A., Shaw, I.F., Shaw, T.V., Shea, B., Shearer, H., Sheldon, S., Shell‐duncan, B., Shepherd, S., Sheridan, L., Siemienska, R., Sillup, G.P., Simeon, J.C., Simonelli, A., Skilodimou, H.D., Škrinjarić, T., Slater, G., Smardon, R., Smith, J., Smoląg, K., Snauwaert, D.T., Soanes‐white, T., Sobocińska, M., Sohaib, O., Soldatić, K., Sorainen, G.T., Soldatos, A., Sørensen, N.N., Spanu, S., Stadlober, E., Stafford, F., Ștefănescu‐mihăilă, R.O., Stefanini, A., Štefko, R., Steglich, E., Steirer, G., Stephenson, M.O., Stoecker, R., Stoffelen, A., Strang, A., Suppa, D., Sutton, J., Svobodová, L., Swigon, M., Synnott, J., Sytsma, V., Tabe, T., Tajeddini, K., Tang, S., Taylor, B., Taylor, C., Teignier, M., Teixeira, C., Tempelaar, D., Ter Avest, K.H., Ter Horst, E., Testa, M.R., Thakur, N., Thiamwong, L., Thijsen, A., Thomas, B.A., Thompson, C., Thompson, D., Tisdall, K., Toft, Mancini, Torell, A., Toscano‐hernández, G., Tregua, A.E., Triandafyllidou, M., Tseloni, A., Seloni, A., Tsikouras, P., Tsogas, G., Twamley, K., Tyler, D.U., Haque, A., Underwood, M., Urbański, M., Uribe‐toril, J., Vaezipour, A., Van Hove, L.V., Huylenbroeck, G., Van Nuland, S., Vanner, C., Vázquez‐cano, E., Veen, E., Veintimilla, S.G.-A., Veković, M., Velija, P., Venco, E.M., Verticelli, A., Vicente, P.V., Estiarte, C., Višnjić, A., Visvizi, A., Vlasblom, J.D., Volsche, S.V., Fintel, D., Von Keyserlingk, L., Vranješević, J., Walter, K.V., Wandosell, G., Wang, Y., Wasileski, G., Wastl‐walter, D., Weaving, C., Weenik, D., Wehr, K., Wei, X., Wharton, A., White, G., Whitehouse, H., Whitley, C.T., Whitman, L., Wiersma‐mosley, J.D., Wilcke, H., Wilkes, R., Williams, L., Williamson, R.D., Wimalasena, L., Wiseman, A., Wołek, M., Wright, E.Q., Wroblewski, A., Wyile, A.S., Wynn, C., Xu, X., Xue, B., Yang, J., Yoe, T.M., Young, M., Younus, M., Yu, T.-F., Yuan, Q., Zadra, C., Zaharijević, A., Zajda, J., Zander, K., Zbuchea, A., Zelin, A., Zhang, C., Zippel, K., Zitricky, V., Živanović, P., Zou, L., Zufferey, C., Zuhdi, M., and Zumeta, W.M.
- Published
- 2020
33. Poster Session Wednesday 5 December all day DisplayDeterminants of left ventricular performance
- Author
-
Del Valle, D Iglesias, Lopez-Fernandez, T, Gemma, D, Gomez-Rubin, MC, De Torres, F, Feliu, J, Canales, M, Buno, A, Ramirez, E, and Lopez-Sendon, JL
- Published
- 2012
34. Development of a new affinity immobilization procedure on functionalized graphite electrodes for proteins tagged to cholinebinding modules: P14-33
- Author
-
Bello, D., Maestro, B., Fonseca, J., Feliu, J. M., Climent, V., and Sanz, J. M.
- Published
- 2012
35. Internet use by cancer patients: should oncologists ‘prescribe’ accurate web sites in combination with chemotherapy? A survey in a Spanish cohort
- Author
-
López-Gómez, M., Ortega, C., Suárez, I., Serralta, G., Madero, R., Gómez-Raposo, C., Sereno, M., Casado, E., Espinosa, E., Lobo, F., and Feliu, J.
- Published
- 2012
- Full Text
- View/download PDF
36. 11P Molecular profiling and targeted therapy in cholangiocarcinoma
- Author
-
de Santayana, M. García Pardo, primary, Ortega, L., additional, Feliu, J., additional, Adeva, J., additional, Fernandez Montes, A., additional, Rodríguez Alonso, R.M., additional, López, C., additional, Rubiales, S., additional, Vera, R., additional, Ghanem Canyete, I., additional, Pazo Cid, R.A., additional, Macarullá, T., additional, López Muñoz, A.M., additional, de la Cámara, J., additional, Ors Castaño, M., additional, Llorca, C., additional, Jiménez Gordo, A., additional, García Palacios, L., additional, García Alfonso, P., additional, and Muñoz Martín, A.J., additional
- Published
- 2020
- Full Text
- View/download PDF
37. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
- Author
-
Gomez, O. Higuera, primary, Soto, V. Heredia, additional, Machado, I., additional, Mendez, M.C., additional, Cuatrecasas, M., additional, Horndler, C., additional, Vermeulen, L., additional, Hoorn, S. Ten, additional, Mendiola, M., additional, Martín-Richard, M., additional, Ruiz-Casado, A., additional, Galvez, E., additional, Aparicio, J., additional, García, I. Sevilla, additional, Leno, R., additional, Fernández-Martos, C., additional, Alonso-Orduna, V., additional, Montes, A. Fernandez, additional, Maurel, J., additional, and Feliu, J., additional
- Published
- 2020
- Full Text
- View/download PDF
38. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
- Author
-
Seguí, E., primary, Alonso-Orduna, V., additional, Sesma, A., additional, Martin-Richard, M., additional, Salud, A., additional, Fernández-Montes, A., additional, Fernández-Martos, C., additional, Ruiz-Casado, A., additional, Gallego, J., additional, Aparicio, J., additional, Gálvez, E., additional, Manzano, H., additional, Alcaide-Garcia, J., additional, Gallego, R., additional, Falco, E., additional, Esposito, F., additional, Oliveres, H., additional, Torres, F., additional, Feliu, J., additional, and Maurel, J., additional
- Published
- 2020
- Full Text
- View/download PDF
39. P-252 Serial cytokines as potential predictive/prognosis biomarkers in potentially resectable pancreatic adenocarcinoma
- Author
-
Borja, I. González, primary, Irigoyen, J. Fernández, additional, Goñi, S., additional, Ghanem, I., additional, Amat, I., additional, Arrazubi, V., additional, Sanz, J. Pérez, additional, Hernandez-Garcia, I., additional, Vera, R., additional, Feliu, J., additional, and Viudez, A., additional
- Published
- 2020
- Full Text
- View/download PDF
40. A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)
- Author
-
Hidalgo, M., primary, Semenisty, V., additional, Bockorny, B., additional, Borazanci, E., additional, von Hoff, D.D., additional, Feliu, J., additional, Sarvise, M. Ponz, additional, Abad, D. Gutierrez, additional, Peled, A., additional, Bohana-Kashtan, O., additional, Gozlan, Y., additional, Sorani, E., additional, Chaney, M., additional, Kadosh, S., additional, Vainstein, A.V., additional, and Macarulla, T., additional
- Published
- 2019
- Full Text
- View/download PDF
41. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
- Author
-
García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, and Maurel J
- Subjects
Clinical score ,Cetuximab ,neoplasms ,Colorectal cancer ,Biomarkers - Abstract
Background RAS testing is used to select patients with anti-epidermal growth factor receptor (EGFR) therapies sensitivity in metastatic colorectal cancer (mCRC). However, other biomarkers such as BRAF, PIK3CA/PTEN, and p-IGF-1R+/MMP7+ (double positive [DP] phenotype) have not been prospectively assessed to predict anti-EGFR resistance. Materials and Methods We designed a multicenter prospective trial (NCT01276379) to evaluate whether the biomarkers BRAF mutation, PIK3CA mutation/PTEN loss, and DP phenotype can improve the prediction for 12-months progression-free survival (PFS) over the use of clinical variables exclusively in patients with RAS wild-type (WT) mCRC treated with standard chemotherapy plus biweekly cetuximab as first-line therapy. The planned sample size was 170 RAS WT patients to detect a 20% difference in 12-month PFS based on the analysis of clinical and selected biomarkers (alpha = .05, beta = .2). The discriminatory capacity of the biomarkers was evaluated using receiver operating characteristic curves. Results We included 181 RAS WT patients. The biomarker distribution was as follows: BRAF mutant, 20 patients (11%); PIK3CA mutated/PTEN loss, 98 patients (58%); DP, 23 patients (12.7%). The clinical variables in the clinical score were progression status >0, left-sided tumor, and resectable liver metastasis as the only metastatic site. The area under the curve (AUC) of the score containing the clinical variables was 0.67 (95% confidence interval [CI], 0.60-0.75). The AUC of the score with clinical variables and BRAF mutational status was 0.68 (0.61-0.75, p = .37). The AUC of the score with clinical variables and PI3KCA mutation/PTEN status was 0.69 (0.61-0.76, p = .32). The AUC of the score with clinical variables and DP phenotype was 0.66 (0.58-0.73, p = .09). Conclusion The addition of BRAF, PIK3CA/PTEN, and DP to a clinical score does not improve the discrimination of 12-month PFS. Implications for Practice This prospective biomarker design study has important clinical implications because many prospective clinical trials are designed with the hypothesis that BRAF mutation per se and MEK and PIK3CA downstream pathways are critical for colorectal tumor survival. The results lead to the question of whether these pathways should be considered as passengers instead of drivers.
- Published
- 2019
42. La infusión de linfocitos efectores autólogos en combinación con rituximab de mantenimiento
- Author
-
Carbo, E.P., Munoz, R.G., de Cerio, A.L.D., Panizo, A., Feliu, J., Giraldo, P., Calvillo, M.R., Grande, C., Olave, T., Andrade, M., Bandres, E., Nunez, J., Calle, N.M., Inoges, S., and Panizo, C.
- Abstract
SP-004 Introducción: La combinación de anticuerpos monoclonales anti CD20 con varios regimenes de quimioterapia se considera el tratamiento estándar en pacientes con linfoma folicular (LF). A pesar de los buenos resultados de este tratamiento, un porcentaje importante de los pacientes no se beneficia de esta terapia ensombreciendo de manera considerable su pronóstico. Nuestra hipótesis es que el tratamiento con una suspensión de linfocitos efectores autólogos expandidos ex vivo (células LAK) podría potenciar el efecto biológico del tratamiento con rituximab (R) mediante el incremento de la actividad ADCC. Investigamos la toxicidad y eficacia de dicho tratamiento con un ensayo clínico fase II. Métodos: Entre 2010 y 2012 se reclutaron 20 pacientes con LF en respuesta tras una primera línea de tratamiento con R-CHOP. El objetivo primario de este ensayo, multicéntrico, prospectivo y de un solo brazo fue evaluar la seguridad y eficacia de la infusión de células LAK (administradas cuatrimestralmente en los ciclos pares de R) en combinación con la pauta estándar de R de mantenimiento bimestral durante 2 años. La producción de células LAK se realizó a partir de células de sangre periférica extraídas en los ciclos impares de R para aislar células mononucleadas y estimularlas y expandirlas en cultivo con interleukina-2 durante 8 semanas. Uno de los objetivos secundarios del ensayo fue la evaluación de los fenotipos celulares y de la potencia biológica de las células LAK midiendo su actividad citotóxica. Este ensayo está registrado en ClinicalTrials.gov con número NCT01329354 Resultados: Se registraron 29 eventos adversos (EA) relacionados con la infusión de las células LAK. Las artralgias y las ...
- Published
- 2019
43. Improving the monitoring of methanol concentration during high cell density fermentation of Pichia pastoris
- Author
-
Ramon, R., Feliu, J. X., Cos, O., Montesinos, J. L., Berthet, F. X., and Valero, F.
- Published
- 2004
- Full Text
- View/download PDF
44. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas
- Author
-
Feliu, J., Mel, R., Borrega, P., Gómez, L. López, Escudero, P., Dorta, J., Castro, J., Vázquez-Estévez, S. E., Bolaños, M., Espinosa, E., and Barón, M. González
- Published
- 2002
45. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy
- Author
-
Feliu, J., Calvillo, J., Escribano, A., de Castro, J., Sánchez, M. E., Mata, A., Espinosa, E., Grande, A. García, Mateo, A., and Barón, M. González
- Published
- 2002
46. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study
- Author
-
Feliu, J., Martín, G., Lizón, J., Chacón, J. I., Dorta, J., de Castro, J., Rodríguez, A., Heras, B. Sánchez, Torrego, J. C., Espinosa, E., and Barón, M. González
- Published
- 2001
47. Phase II study of gemcitabine (G) in combination with docetaxel (D) in advanced non-small-cell lung cancer (NSCLC) patients. (Oncopaz and Hospitals Associated).
- Author
-
García, C., Milla, A, Feliu, J, Lorenzo, A, Madroñal, C, Gili, F, and Baena, J M
- Published
- 2000
48. Sequential chemotherapy with paclitaxel, cisplatin, Gemcitabine and vinorelbine in advanced non-small-cell lung cancer: A phase II study.
- Author
-
Barón, Manuel González, Ordóñez, A., Martin, G., Dorta, J., Murias, A., Madroñal, C., Feliu, J., Lizón, J., Aguiar, J., and Vázquez, Y.
- Published
- 2000
49. Delphi consensus of an expert committee in oncogeriatrics regarding comprehensive geriatric assessment in seniors with cancer in Spain
- Author
-
Molina-Garrido MJ, Guillén-Ponce C, Blanco R, Saldana, J, Feliu, J, Antonio, M, Lopez-Mongil, R, Ramos Cordero, P, Girones, R, and Spanish Soc Med Oncology SEOM
- Subjects
Consensus ,Delphi method ,Oncogeriatrics ,Comprehensive geriatric assessment - Abstract
Objectives: The aim of this work was to reach a national consensus in Spain regarding the Comprehensive Geriatric Assessment (CGA) domains in older oncological patients and the CGA scales to be used as a foundation for widespread use. Material and Methods: The Delphi method was implemented to attain consensus. Representatives of the panel were chosen from among the members of the Oncogeriatric Working Group of the Spanish Society of Medical Oncology (SEOM). Consensus was defined as >= 66.7% coincidence in responses and by the stability of said coincidence (changes
- Published
- 2018
50. Can we avoid the toxicity of chemotherapy in elderly cancer patients?
- Author
-
Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C, and Molina-Garrido MJ
- Subjects
Elderly ,Toxicity ,Chemotherapy ,Risk score ,Geriatric assessment ,Cancer - Abstract
Although approximately 50% of cancer patients are 70 years of age or older, cancer treatment in the elderly remains a therapeutic challenge. The elderly form a very heterogeneous group in relation to their general health state, degree of dependence, comorbidities, performance status, physical reserve and geriatric situation, for which therapeutic decisions must be made in an individualized manner. In addition, changes in pharmacokinetics and pharmacodynamics of the drugs occur with age, as well as the tolerance of the tissues, leading to a narrowing of the therapeutic margin and an increase in toxicity. In the general population, Performace Status (PS) has traditionally been used to estimate tolerance to chemotherapy, but in the elderly population it is not useful. In this review we summarize the current knowledge about the pharmacology of antineoplastic drugs in the elderly and the tools available to help us identify risk of chemotherapy toxicity in these patients.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.